Abstract: In various embodiments, provided herein are pamoate salts of monoamine Anti-Parkinsons disease agents including rotigotine, ropinirole, pramipexole, selegiline, rasagiline, and safinamide, pharmaceutical composition comprising the same, methods of preparing the same, and methods of using the same. For example, the pamoate salt herein can be characterized by a molar ratio of rotigotine, ropinirole, pramipexole, selegiline, rasagiline, or safinamide to pamoic acid of about 1:1 or about 2:1. The pamoate salt herein can also be crystalline including anhydrous, hydrate or solvate forms, or their polymorphs, or amorphous. The pamoate salts described herein can provide a long acting and/or extended release profile of the monoamine agents for the treatment of Parkinsons disease (PD). Thus, also provided herein are methods of preparing a long acting and/or extended release injectable formulation of the monoamine agents using their respective pamoate salts.
Abstract: The present invention concerns novel pharmaceutically active triterpene amine derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the triterpene amine compounds. Specifically, the compounds are derivatives of betulinic acid having substitutions at one or more of the C-3, C-28 and C-19 positions as further described herein. The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus-1 (HIV-1).
Type:
Grant
Filed:
June 28, 2019
Date of Patent:
February 1, 2022
Assignees:
DFH THERAPEUTICS, The United States Of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Theodore J. Nitz, Carl T. Wild, David E. Martin, Eric O. Freed
Abstract: The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use as kallikrein inhibitors in therapy.
Type:
Grant
Filed:
June 1, 2017
Date of Patent:
January 25, 2022
Assignee:
KalVista Pharmaceuticals Limited
Inventors:
Haydn Beaton, David Malcolm Crowe, Hannah Joy Edwards, Nicholas James Griffiths-Haynes
Abstract: The present invention provides compositions and methods for treating hypertension and obstructive sleep apnea utilizing hydrogel compositions comprising drug amphiphiles with TRPM 7 antagonists for use in a subject, including use on the carotid body of a subject.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
January 25, 2022
Assignee:
THE JOHNS HOPKINS UNIVERSITY
Inventors:
Vsevolod Polotsky, Honggang Cui, Roxana Elena Mitrut, Mi-kyung Shin
Abstract: The present invention provides a novel crystalline form of Valbenazine dibesylate, Valbenazine dibesylate Form APO-I, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of hyperkinetic disorders, including tardive dyskinesia.
Type:
Grant
Filed:
December 18, 2019
Date of Patent:
January 11, 2022
Assignee:
Apotex Inc.
Inventors:
Mohammed Abdul Raheem, Yajun Zhao, Minh T. N. Nguyen, Mohamed Ibrahim Zaki, Jenny L. Gerster, Stuart P. Green, Allan W. Rey
Abstract: The present invention encompasses compounds of formula (I) wherein the groups R2 to R5, A, X and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
Type:
Grant
Filed:
May 19, 2017
Date of Patent:
January 4, 2022
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Harald Engelhardt, Heribert Arnhof, Sebastian Carotta, Marco Hans Hofmann, Marc Kerenyi, Dirk Scharn
Abstract: The invention provides compounds and methods of treating autophagy mediated diseases and disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits.
Abstract: The present invention relates to a compound formed by entinostat as shown in formula (I) and acidic counterion. Compared with the known solid form of entinostat, the compound involved has advantages in terms of solubility, stability, etc. The present invention also relates to a crystalline form of the compound and a preparation method therefor, a pharmaceutical composition thereof and the use thereof in the preparation of a drug for preventing and/or treating a disease associated with differentiation or proliferation.
Abstract: The poly(pro-drug) material includes one or more alternating therapeutic compounds and biodegradable hydrocarbyl groups. The therapeutic compounds and biodegradable hydrocarbyl groups are separated by cleavable linker compounds. The therapeutic compounds, such as estrogen, curcumin, and fingolimod, include a plurality of substitutable functional groups that provide reaction sites for complexing with the cleavable linkers and in turn one or more polymers, such that the poly(pro-drug) material ends up composed of the therapeutic compound itself. In aqueous media and at physiological temperature and pH, the poly(pro-drug) materials degrade to release the therapeutic compounds from the material with a zero-order release profile. Advantageously, the poly(pro-drug) materials release the therapeutic compounds on time scales of years. The poly(pro-drug) materials also exhibit reduced to allow for prolonged implantation within a patient.
Type:
Grant
Filed:
October 16, 2019
Date of Patent:
December 21, 2021
Assignee:
Rensselaer Polytechnic Institute
Inventors:
Edmund Francis Palermo, Anthony Richard D'Amato, Ryan J. Gilbert, Samuel Ellman
Abstract: Disclosed are a pentacyclic triterpene compound as shown in general formula (I) and a preparation method therefor. The compound has an effective antagonistic effect on FXR receptors.
Type:
Grant
Filed:
September 17, 2018
Date of Patent:
December 7, 2021
Assignee:
SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Abstract: The present invention relates to the reduction of the side-effects induced by tetrabenazine or other inhibitors of vesicular monoamine transporter (VMAT), in the treatment of central nervous system disorders such as Huntington's disease, L-DOPA-induced dyskinesias in Parkinson's disease, Tourette's syndrome or tardive dyskinesia. The invention comprises administering to a patient in need thereof an effective amount of activates selective serotonin 5-HT1A receptors agonist, whereby the side-effects of depression or Parkinsonism induced by tetrabenazine or other VMAT inhibitors are minimized.
Type:
Grant
Filed:
July 20, 2018
Date of Patent:
December 7, 2021
Assignees:
Neurolixis, Uniwersytet Jagiellonski Collegium Medicum
Inventors:
Anna Wesolowska, Magdalena Jastrzebska-Wiesek, Adrian Newman-Tancredi, Mark Andrew Varney
Abstract: An organic compound represented by formula (1) and an organic compound represented by formula (2). These organic compounds provide high color purity. In formulae (1) and (2), R1 to R24 are each independently selected from the group consisting of a hydrogen atom and a substituent.
Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
Type:
Grant
Filed:
December 21, 2017
Date of Patent:
December 7, 2021
Assignee:
ARVINAS OPERATIONS, INC.
Inventors:
Andrew P. Crew, Lawrence B. Snyder, Jing Wang, Yimin Qian, Michael Berlin
Abstract: An organic compound that emits red light having a long wavelength and that is represented by formula [1] below. In the formula [1], R1 to R24 are each independently selected from a hydrogen atom or a substituent.
Type:
Grant
Filed:
September 27, 2019
Date of Patent:
December 7, 2021
Assignee:
Canon Kabushiki Kaisha
Inventors:
Hironobu Iwawaki, Jun Kamatani, Naoki Yamada
Abstract: Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.
Abstract: Pyridine compounds of Formula (1) are provided: wherein R1, R2, X, Y and Het are defined. The pyridine compounds can be used to treat or prevent plant diseases.